Dec 5 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* Sorrento Therapeutics Inc - study for lead investigational product, ztlido has met a primary endpoint
* Sorrento subsidiary, Scilex Pharmaceuticals announces key endpoints met in pivotal bioequivalence clinical study for its lead product, ztlido
* Scilex Pharmaceuticals Inc - full data will be resubmitted to FDA as part of 505(B)(2) new drug application (NDA) in mid-2017 Source text for Eikon: ID:nPn4xXc9Na Further company coverage: SRNE.O